anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We are applying for general permission to acquire magnetic resonance (MR) data from normal volunteers. Data will be used to develop and test MR protocols for subsequent clinical research, and to support methodological research into MR techniques: improving the speed, quality, and range of measurements possible with the scanner. This application is restricted to the non-invasive imaging of healthy adults. It excludes interventional MR procedures, injections of MR contrast agents, and all other invasive techniques. MR imaging has been performed on millions of subjects worldwide without ill effect: there are well-established contraindications for MR, particularly associated with metal in the body, and when these are followed residual risk is low. Scans will be performed on commercially available MR systems at UCLH, with their internal monitoring and safety devices always enabled. Scans will be connected with several research projects, but in each case it is the scanning technique (the programmed sequence of data acquisition and processing steps) which will vary. The volunteer experience will be similar, and all ethical and consent details will be identical. These scans are for methodological research on the MR techniques themselves, and will never form part of the volunteer's own healthcare. Volunteers will normally be recruited from within the medical physics department. Before scanning, the volunteer will undergo safety screening (a questionnaire, backed up by explanation from an MR radiographer or experienced MR physicist). If there are no contraindications to the scan, the volunteer will then be placed on a table inside the MR scanner. Ear protection will be provided. Occasionally, small temporary surface makers (usually ordinary cod liver oil capsules) may be placed on the volunteer's skin to allow positions to be identified between scans. Appropriate MR coils (receivers in plastic moldings, connected to the scanner by a cable) will usually be placed around the body part being imaged. Imaging will be carried out for a variable period of time not exceeding two hours. During the procedure, the volunteer may sometimes be asked to hold their breath or move in certain ways. Microphones, speakers, and an emergency buzzer allow the volunteer to remain in verbal contact with the person operating the scanner, and to request that the scan be terminated at any time for any reason. Normally, individual scans are independent. Occasionally a volunteer may be asked in advance to attend for more than one scan, to check that a newly designed measurement is reproducible across different visits. (It is anticipated, however, that some individuals will volunteer for several independent scans.)
<PICT:0441513/IV/1> A vitamin concentrate is prepared from fish liver oils and the like by saponifying, adding a solvent for the unsaponifiable portion within the limit that the soap solution can take up, and then extracting the unsaponifiable portion with an additional quantity of the solvent in counter-current.  In an example, cod-liver or other oil or fat mixed with alcohol is saponified with caustic soda at 70 DEG  C., then cooled to 50 DEG  C. and diluted with 25 per cent alcohol.  Ethylene dichloride is then added in sufficient quantity to raise the specific gravity to 1,024 or as much as the solution will take up, and the unsaponifiable portion is then extracted by means of additional ethylene dichloride in counter-current.  The soap solution is supplied from a tank A to the bottom of a column 14 containing Raschig rings and initially filled with solvent.  Ethylene dichloride is supplied at the top of the column from a tank B.  The extract is collected in a receiver C and the exhausted soap solution in a tank D.  The extract may be concentrated in vacuo, washed with water or with a solution of a salting-out agent such as sodium chloride or sulphate or calcium chloride, and any remaining solvent may be removed by distillation at a temperature not exceeding 60 DEG  C. Instead of ethylene dichloride, other solvents such as ether, petroleum ether, or carbon tetrachloride may be used.
Electromechanical reciprocity - comprising electro-mechanical (EMC) and mechano-electric coupling (MEC) - provides cardiac adaptation to changing physiological demands. Understanding electromechanical reciprocity and its impact on function and heterogeneity in pathological conditions - such as (drug-induced) acquired long QT syndrome (aLQTS) - might lead to novel insights in arrhythmogenesis. Our aim is to investigate how electrical changes impact on mechanical function (EMC) and vice versa (MEC) under physiological conditions and in aLQTS. To measure regional differences in EMC and MEC in vivo, we used tissue phase mapping cardiac MRI and a 24-lead ECG vest in healthy (control) and IKr-blocker E-4031-induced aLQTS rabbit hearts. MEC was studied in vivo by acutely increasing cardiac preload, and ex vivo by using voltage optical mapping (OM) in beating hearts at different preloads. In aLQTS, electrical repolarization (heart rate corrected RT-interval, RTn370) was prolonged compared to control (P < 0.0001) with increased spatial and temporal RT heterogeneity (P < 0.01). Changing electrical function (in aLQTS) resulted in significantly reduced diastolic mechanical function and prolonged contraction duration (EMC), causing increased apico-basal mechanical heterogeneity. Increased preload acutely prolonged RTn370 in both control and aLQTS hearts (MEC). This effect was more pronounced in aLQTS (P < 0.0001). Additionally, regional RT-dispersion increased in aLQTS. Motion-correction allowed us to determine APD-prolongation in beating aLQTS hearts, but limited motion correction accuracy upon preload-changes prevented a clear analysis of MEC ex vivo. Mechano-induced RT-prolongation and increased heterogeneity were more pronounced in aLQTS than in healthy hearts. Acute MEC effects may play an additional role in LQT-related arrhythmogenesis, warranting further mechanistic investigations. KEY POINTS: Electromechanical reciprocity comprising excitation-contraction coupling (EMC) and mechano-electric feedback loops (MEC) is essential for physiological cardiac function. Alterations in electrical and/or mechanical heterogeneity are known to have potentially pro-arrhythmic effects. In this study, we aimed to investigate how electrical changes impact on the mechanical function (EMC) and vice versa (MEC) both under physiological conditions (control) and in acquired long QT syndrome (aLQTS). We show that changing the electrical function (in aLQTS) results in significantly altered mechanical heterogeneity via EMC and, vice versa, that increasing the preload acutely prolongs repolarization duration and increases electrical heterogeneity, particularly in aLQTS as compared to control. Our results substantiate the hypothesis that LQTS is an 'electro-mechanical', rather than a 'purely electrical', disease and suggest that acute MEC effects may play an additional role in LQT-related arrhythmogenesis.
This study was single-blind, randomized controlled trial. Clients were randomly assigned by blocked randomization (block size 4) to either the experimental group (occupational therapy that included assessment and adjustment of the challenge-skill balance of the activities) or to the control group (occupational therapy as normally conducted at the day care center). Randomization was stratified by sex and EuroQol visual analogue scale, resulting in four layers. The primary outcome was change in health-related quality of life after 10 sessions of occupational therapy. Clients were assessed before the intervention (pre-test) and after the 10th session (post-test). Significant differences were observed in the EuroQol-5 Dimension (EQ-5D) score and in the Medical Outcome Study 8-Item Short-Form Health Survey (SF-8) scores for general health, physical functioning , and vitality.
Previous studies have suggested a possible link between autoimmune diseases and graft dysfunction; however, a causal link remains unclear. Exposure factors were set as 13 autoimmune diseases, and outcomes were set as graft dysfunction. Mendelian randomization was used to analyze the causal link between exposure and outcome. Alopecia areata and asthma were linked to graft dysfunction (odds ratio 0.828; 95% confidence interval 0.699-0.980; P = .029; odds ratio 1.79; 95% confidence interval 1.069-2.996; P = .027). At the same time, primary sclerosing cholangitis was found to be heterogeneous as an exposure factor (P = .009), but no heterogeneity or pleiotropy was found in other exposure factors. Our preliminary findings show 2 autoimmune diseases as risk factors for graft dysfunction, 1 autoimmune disease as a protective factor for graft dysfunction and the mechanisms remain to be understood.
<P>PROBLEM TO BE SOLVED: To establish a new technique with which useful components contained in rooibos tea (Asparasus linearis or Asparasus cederbergensis) can efficiently be utilized and to provide a useful substance suitable as a raw material, etc., for beverages, food materials, food additives or cosmetics.  <P>SOLUTION: The method for producing epidermal powder of the Asparasus linearis or Asparasus cederbergensis comprises a step of mixing stems of the Asparasus linearis or Asparasus cederbergensis while mutually rubbing the stems, thereby peeling the epidermis of the stems and powdering the peeled epidermis. The powder consisting essentially of the epidermis of the stems of the Asparasus linearis or Asparasus cederbergensis is obtained by the method. A step of humidifying the stems at a low temperature is added before the step of rubbing and mixing the stems. Furthermore, the step of rubbing and mixing the stems is preferably carried out while feeding dry hot air at a higher temperature than that in the step of humidifying the stems at the low temperature.  <P>COPYRIGHT: (C)2004,JPO
Exposure to pesticide residues during the first 1000 days of life can disrupt body homeostasis and contribute to chronic metabolic diseases. Perinatal chlorpyrifos (CPF) exposure alters gut microbiota (GM) balance, potentially affecting offspring's health. Given the GM influence on brain function, the primary aim is to determine if pesticide-induced dysbiosis (microbial imbalance) affects indirectly other organs, such as the blood-brain barrier (BBB). The secondary objective is to evaluate the prebiotics protective effects, particularly inulin in promoting microbial balance (symbiosis), in both mothers and offspring. A total of 15 or more female rats were divided in 4 groups: control, oral CPF-exposed (1 mg/kg/day), exposed to inulin (10 g/L), and co-exposed to CPF and inulin from pre-gestation until weaning of pups. Samples from intestines, spleen, liver, and brain microvessels underwent microbiological and biomolecular analyses. Bacterial culture assessed GM composition of living bacteria and their translocation to non-intestinal organs. RT qPCR and Western blotting detected gene expression and protein levels of tight junction markers in brain microvessels. CPF exposure caused gut dysbiosis in offspring, with decreased Lactobacillus and Bifidobacterium and increased Escherichia coli (p < 0.01) leading to bacterial translocation to the spleen and liver. CPF also decreased tight junction's gene expression levels (50 to 60% decrease of CLDN3, p < 0.05). In contrast, inulin partially mitigated these adverse effects and restored gene expression to control levels. Our findings demonstrate a causal link between GM alterations and BBB integrity disruptions. The protective effects of inulin suggest potential therapeutic strategies to counteract pesticide-induced dysbiosis.
A preparation, in particular a cosmetic preparation, in the form of a workable paste which is present in the form of a W/O emulsion and which is suitable for cosmetic uses, in particular in the area of decorative cosmetics for coloring and improving the skin, the lips and the eyelids. It is also suitable as a fixing for lipstick, as lip care, as a skin care foundation or as a sun protection agent. It is preferably in the form of a water-in-silicone emulsion. It contains a wax, a suitable emulsifier, a volatile silicone oil, a moistening agent, a solid phase and water. In addition it may also contain the additives and adjuvant substances which are approved and usual in cosmetics. Processes for the production of the preparation are also described.
FIELD: medicine. SUBSTANCE: method involves applying 3-5% motherwort infusion that is taken during 10-15 days twice a in the amount of 100 ml in evening time. Physiotherapeutic action is carried out with alternating magnetic field on nose region. Field strength is 20-30 mT, frequency is 25-50 Hz during 10- 12 days each procedure being 10-15 min long. Then motherwort infusion is to be taken during 10 days and more at least twice a year. EFFECT: enhanced effectiveness of treatment. 2 cl
Prolonged use of topical anti-bacterial agents may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to sulfonamides may also develop.

Ophthalmic ointments may retard corneal wound healing.

The effectiveness of sulfonamides may be reduced by the para-aminobenzoic acid present in the purulent exudates. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration, and cross-sensitivity between different sulfonamides may occur.

At the first sign of hypersensitivity, increase in purulent discharge, or aggravation of inflammation or pain, the patient should discontinue use of the medication and consult a physician (see WARNINGS).
This was a two-arm parallel randomized controlled trial, in which 116 and 114 participants were assigned to the experimental and control groups, respectively. The mHealth intervention in this study had been pilot tested and tailored. Specifically, the experimental group received a medication-taking reminder every morning via WeChat app and educational materials of coronary heart disease and medication adherence every five days via Message Express app. The control group received only general educational materials, which were irrelevant to coronary heart disease or medication adherence, every 5 days via Message Express app. All participants were diagnosed with coronary heart disease. The specific recruitment criteria of participants had been published in peer-reviewed journal.
BACKGROUND: Osteoarthritis (OA), a degenerative joint disorder, is a major reason of disability in adults. Accumulating evidences have proved that bone marrow mesenchymal stem cells (BMSCs)-carried exosomes play a significant therapeutic effect on OA. However, the precise regulatory network remains unknown.
METHODS: OA and normal cartilage samples were acquired from patients, and chondrocytes were exposed to IL-1β to conduct a cellular OA model. Exosomes prepared from BMSCs were identified using nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Cell viability was determined with CCK-8 assay. Inflammatory injury was assessed by LDH and inflammatory factors (TNF-α and IL-6) using corresponding ELISA kits, respectively. Ferroptosis was evaluated by GSH, MDA and iron levels using corresponding kits, and ROS level with DCFH-DA. The expressions of genes/proteins were determined with RT-qPCR/western bolt. RNA immunoprecipitation and luciferase activity assay were conducted for testing the interactions of small nucleolar RNA host gene 7 (SNHG7)/ferroptosis suppressor protein 1 (FSP1) and miR-485-5p.
RESULTS: The expressions of SNHG7 and FSP1 were both reduced in IL-1β-induced chondrocytes and OA cartilage tissues, and there was a positive correlation between them in clinical level. Moreover, SNHG7 was enriched in BMSCs-derived exosomes (BMSCs-Exos) and could be internalized by chondrocytes. Functional analysis illustrated that BMSCs-Exos administration repressed inflammatory injury, oxidative stress and ferroptosis in IL-1β-induced chondrocytes, while these changes were reinforced when SNHG7 was overexpressed in BMSCs-Exos. Notably, FSP1 silencing in chondrocytes abolished the beneficial effects mediated by exosomal SNHG7.
CONCLUSIONS: Exosomal SNHG7 released from BMSCs inhibited inflammation and ferroptosis in IL-1β-induced chondrocytes through miR-485-5p/FSP1 axis. This work suggested that BMSCs-derived exosomal SNHG7 would be a prospective target for OA treatment.
* The total volume of infusion is determined by the patient's body weight and should be administered over approximately 4 hours. 
  * Administer LUMIZYME using an in-line low protein binding 0.2-micron filter.
  * Infusions should be administered in a step-wise manner using an infusion pump. The initial infusion rate should be no more than 1 mg/kg/hr. The infusion rate may be increased by 2 mg/kg/hr every 30 minutes, after patient tolerance to the infusion rate is established, until a maximum rate of 7 mg/kg/hr is reached. 
  * Vital signs should be obtained at the end of each step. If the patient is stable, LUMIZYME may be administered at the maximum rate of 7 mg/kg/hr until the infusion is completed. 
  * The infusion rate may be slowed or temporarily stopped in the event of mild to moderate hypersensitivity reactions. In the event of anaphylaxis or severe hypersensitivity reaction, immediately discontinue administration of LUMIZYME and initiate appropriate medical treatment. See Table 1 below for the rate of infusion at each step, expressed as mL/hr based on the recommended infusion volume by patient weight.
  * Do not infuse LUMIZYME in the same intravenous line with other products. Discard any unused product.
Participants in the control group will be asked to fill out online surveys and book appointments for blood sample collection and weight measurements at the beginning and at the end of the study. In addition, participants will be asked to report their weight two more times during the study (in months 2 and 4) with an online survey that will be sent via the MyBiobank portal. The participation in the study ends with another personal visit to the clinic for blood sampling and weight measurement six months after registration. No other personal advice or support is provided to this group.
The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro 115 antibody and a method of alleviating or treating an Pro 115 -expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti- Pro115 antibody to the mammal.
2149116 9411006 PCTABS00032 Substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, including compositions containing same and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of Tumor Necrosis Factor Alpha (TNF-.alpha.) can be either inhibited or augmented selectively by administration to the host of effective amounts of substances or their compositions comprising specific oligosaccharides in substantially purified form. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-.alpha.. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week.
INTRODUCTION: Surgical stabilization of rib fractures (SSRF) is associated with lower rates of mortality and fewer complications. This study evaluates whether the decision to undergo SSRF is associated with age, race, ethnicity, and insurance status and assesses associated clinical outcomes.
METHODS: This retrospective analysis included patients ≥45 y old with rib fractures who underwent SSRF in the Trauma Quality Improvement Program from 2016 to 2020. Race, ethnicity, and insurance statuses were collected. Age in years was dichotomized into two groups: 45-64 and 65+. Outcomes included ventilator-associated pneumonia, unplanned endotracheal intubation, acute respiratory distress syndrome, in-hospital mortality, failure to rescue (FTR) after major complications, and FTR after respiratory complications. Logistic regression models were fit to evaluate outcomes, controlling for gender, body mass index, Injury Severity Score, flail chest, chronic obstructive pulmonary disease, congestive heart failure, and smoking.
RESULTS: Two thousand eight hundred thirty-nine patients aged 45-64 and 1828 patients aged 65+ underwent SSRF. No significant difference in clinical outcomes was noted between these groups. Analysis showed that the association of SSRF with ventilator-associated pneumonia, unplanned intubation, acute respiratory distress syndrome, in-hospital mortality, FTR after a major complication, or FTR after a respiratory complication did not vary by age (P > 0.05). Black (odds ratio [OR] 0.67; 95% confidence interval [CI]: 0.59-0.77; P < 0.001), Hispanic (OR 0.80; 95% CI: 0.71-0.91; P < 0.001), and Medicaid (OR = 0.85; 95% CI = 0.76-0.95; P = 0.005) patients were less likely to receive SSRF.
CONCLUSIONS: No differences in clinical outcomes were measured between adults aged 45-64 and ≥65 who underwent SSRF. Older age should not preclude patients from receiving SSRF. Further work is needed to improve underutilization in Black, Hispanic and Medicaid patients.
The invention belongs to the field of biotechnology and medicine, and discloses a new human epididymis specific expression sperm binding protein HEL-48 as well as preparation and application thereof. The invention discloses an amino acid sequence of the HEL-48 protein and provides a recombination expression vector carrying the DNA sequence for encoding the protein. The protein is located in the rear area of the head of a mature sperm. A RT-PCR result shows that the gene is highly expressed in the tissues of epididymis and testis and is lowly expressed in other tissues. A band of about 47 KD is detected in the corpus epididymidis part with Western blot. The HEL-48 protein can be used as a target protein for researching and developing immunity contraceptive as well as clinical diagnosis and treatment for male sterility. A method for detecting a corresponding gene or protein based on development of the HEL-48 protein can be widely used for the research field of reproductive medicine.